Suspected autoimmune myocarditis and cardiac conduction abnormalities with nivolumab therapy for non-small cell lung cancer

BMJ Case Reports

Volumn 2016, Issue , 2016, Pages

  Gibson, Robert ^a   Delaune, Jess ^a   Szady, Anita ^a   Markham, Merry ^b  

^a UNIVERSITY OF FLORIDA COLLEGE OF MEDICINE   (United States)

^b UNIVERSITY OF FLORIDA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AFATINIB; ALANINE AMINOTRANSFERASE; AMIODARONE; ASPARTATE AMINOTRANSFERASE; CARBOPLATIN; CREATINE KINASE; CREATINE KINASE MB; CYTOTOXIC T LYMPHOCYTE ANTIGEN 4; EPIDERMAL GROWTH FACTOR RECEPTOR; ERLOTINIB; FONDAPARINUX; METHYLPREDNISOLONE; NIVOLUMAB; PEMETREXED; PROGRAMMED DEATH 1 RECEPTOR; TROPONIN; ANTINEOPLASTIC AGENT; MONOCLONAL ANTIBODY;

AGED; ALANINE AMINOTRANSFERASE BLOOD LEVEL; ARTICLE; ARTIFICIAL VENTILATION; ASPARTATE AMINOTRANSFERASE BLOOD LEVEL; AUTOIMMUNE DISEASE; AUTOIMMUNE MYOCARDITIS; AUTOPSY; BRADYCARDIA; CANCER CHEMOTHERAPY; CANCER DIAGNOSIS; CANCER GROWTH; CANCER RADIOTHERAPY; CANCER STAGING; CANCER SURGERY; CASE REPORT; CATHETER ABLATION; CYTOREDUCTIVE SURGERY; DEATH; DEEP VEIN THROMBOSIS; DIFFERENTIAL DIAGNOSIS; DRUG DOSE REDUCTION; DRUG INDICATION; DRUG WITHDRAWAL; ELECTROCARDIOGRAM; FEMALE; GASTROINTESTINAL TOXICITY; GENE MUTATION; HEART BLOCK; HEART CATHETERIZATION; HEART MUSCLE CONDUCTION DISTURBANCE; HEART RATE; HEART RIGHT BUNDLE BRANCH BLOCK; HEART VENTRICLE TACHYCARDIA; HOSPITAL ADMISSION; HUMAN; HYPOTENSION; LEFT POSTERIOR FASCICULAR BLOCK; LUNG ADENOCARCINOMA; LUNG EMBOLISM; MENTAL DISEASE; MYOCARDITIS; NAUSEA AND VOMITING; NEUROIMAGING; NUCLEAR MAGNETIC RESONANCE IMAGING; PALLIATIVE THERAPY; PERCUTANEOUS CORONARY INTERVENTION; PLEURA EFFUSION; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; RESPIRATORY DISTRESS; SPINAL CORD METASTASIS; THORAX RADIOGRAPHY; THROMBOCYTOPENIA; TRACHEA STENOSIS; TRANSTHORACIC ECHOCARDIOGRAPHY; TREATMENT CONTRAINDICATION; TREATMENT OUTCOME; TREATMENT RESPONSE; TUMOR BIOPSY; WOLFF PARKINSON WHITE SYNDROME; CARCINOMA, NON-SMALL-CELL LUNG; CHEMICALLY INDUCED; DRUG EFFECTS; ELECTROCARDIOGRAPHY; FATALITY; HEART ARRHYTHMIA; IMMUNOLOGY; LUNG NEOPLASMS;

AGED; ANTIBODIES, MONOCLONAL; ANTINEOPLASTIC AGENTS; ARRHYTHMIAS, CARDIAC; AUTOIMMUNE DISEASES; CARCINOMA, NON-SMALL-CELL LUNG; DIAGNOSIS, DIFFERENTIAL; ELECTROCARDIOGRAPHY; FATAL OUTCOME; FEMALE; HUMANS; LUNG NEOPLASMS; MYOCARDITIS;

EID: 84979527884     PISSN: None     EISSN: 1757790X     Source Type: Journal    
DOI: 10.1136/bcr-2016-216228     Document Type: Article

References (25)

1. Hodi FS, O'Day SJ, McDermott DF, et al. Improved survival with ipilimumab in patients with metastatic melanoma. N Engl J Med 2010;363:711-23.
2. Robert C, Thomas L, Bondarenko I, et al. Ipilimumab plus dacarbazine for previously untreated metastatic melanoma. N Engl J Med 2011;364:2517-26.
3. Mahoney KM, Freeman GJ, McDermott DF. The next immune-checkpoint inhibitors: PD-1/PD-L1 blockade in melanoma. Clin Ther 2015;37:764-82.
4. Page DB, Postow MA, Callahan MK, et al. Immune modulation in cancer with antibodies. Annu Rev Med 2014;65:185-202.
5. Ansell SM, Lesokhin AM, Borrello I, et al. PD-1 blockade with nivolumab in relapsed or refractory Hodgkin's lymphoma. N Engl J Med 2015;372:311-19.
6. Robert C, Ribas A, Wolchok JD, et al. Anti-programmed-death-receptor-1 treatment with pembrolizumab in ipilimumab-refractory advanced melanoma: a randomised dose-comparison cohort of a phase 1 trial. Lancet 2014;384:1109-17.
7. Robert C, Long GV, Brady B, et al. Nivolumab in previously untreated melanoma without BRAF mutation. N Engl J Med 2015;372:320-30.
8. Hamid O, Robert C, Daud A, et al. Safety and tumor responses with lambrolizumab (anti-PD-1) in melanoma. N Engl J Med 2013;369:134-44.
9. Brahmer JR, Tykodi SS, Chow LQ, et al. Safety and activity of anti-PD-L1 antibody in patients with advanced cancer. N Engl J Med 2012;366:2455-65.
10. Topalian SL, Hodi FS, Brahmer JR, et al. Safety, activity, immune correlates of anti-PD-1 antibody in cancer. N Engl J Med 2012;366:2443-54.
11. Martin-Liberal J, Kordbacheh T, Larkin J. Safety of pembrolizumab for the treatment of melanoma. Expert Opin Drug Saf 2015;14:957-64.
12. Villadolid J, Amin A. Immune checkpoint inhibitors in clinical practice: update on management of immune-related toxicities. Transl Lung Cancer Res 2015;4:560-75.
13. Barbee MS, Ogunniyi A, Horvat TZ, et al. Current status and future directions of the immune checkpoint inhibitors ipilimumab, pembrolizumab, nivolumab in oncology. Ann Pharmacother 2015;49:907-37.
14. Kong YC, Flynn JC. Opportunistic autoimmune disorders potentiated by immune-checkpoint inhibitors anti-CTLA-4 and anti-PD-1. Front Immunol 2014;5:206.
15. Wang J, Okazaki IM, Yoshida T, et al. PD-1 deficiency results in the development of fatal myocarditis in MRL mice. Int Immunol 2010;22: 443-52.
16. Tarrio ML, Grabie N, Bu DX, et al. PD-1 protects against inflammation and myocyte damage in T cell-mediated myocarditis. J Immunol 2012;188:4876-84.
17. Tivol EA, Borriello F, Schweitzer AN, et al. Loss of CTLA-4 leads to massive lymphoproliferation and fatal multiorgan tissue destruction, revealing a critical negative regulatory role of CTLA-4. Immunity 1995;3:541-7.
18. Okazaki T, Tanaka Y, Nishio R, et al. Autoantibodies against cardiac troponin I are responsible for dilated cardiomyopathy in PD-1-deficient mice. Nat Med 2003;9:1477-83.
19. Angelini A, Calzolari V, Calabrese F, et al. Myocarditis mimicking acute myocardial infarction: role of endomyocardial biopsy in the differential diagnosis. Heart 2000;84:245-50.
20. Caforio AL, Pankuweit S, Arbustini E, et al. Current state of knowledge on aetiology, diagnosis, management, therapy of myocarditis: a position statement of the European Society of Cardiology Working Group on Myocardial and Pericardial Diseases. Eur Heart J 2013;34:2636-48.
21. Abdel-Aty H, Boyé P, Zagrosek A, et al. Diagnostic performance of cardiovascular magnetic resonance in patients with suspected acute myocarditis: comparison of different approaches. J Am Coll Cardiol 2005;45:1815-22.
22. Laübli H, Balmelli C, Bossard M, et al. Acute heart failure due to autoimmune myocarditis under pembrolizumab treatment for metastatic melanoma. J Immunother Cancer 2015;3:11.
23. Patnaik A, Socinski MA, Gubens MA, et al. Phase 1 study of pembrolizumab (pembro; MK-3475) plus ipilimumab (IPI) as second line therapy for advanced nonsmall cell lung cancer (NSCLC): Keynote-021 cohort D [abstract]. J Clin Oncol 2015;33:8011.
24. Roth ME, Muluneh B, Jensen BC, et al. Left ventricular dysfunction after treatment with ipilimumab for metastatic melanoma. Am J Ther 2016.
25. Nishimura H, Okazaki T, Tanaka Y, et al. Autoimmune dilated cardiomyopathy in PD-1 receptor-deficient mice. Science 2001;291:319-22.